Nippon Steel shares climb 5% after Trump offers support for U.S. Steel deal
Nippon Steel shares climb 5% after Trump offers support for U.S. Steel deal
Source link
Similar Posts
DraftKings Q4: Bold 2025 Ambition But A Corresponding Valuation (Rating Downgrade) (DKNG)
This article was written by Follow I am an avid investor with a major focus on small cap companies with experience in investing in US, Canadian, and European markets. My investment philosophy to generating great returns on the stock market revolves around identifying mispriced securities by understanding the drivers behind a company’s financials, and ultimately,…
The Great Rotation
The Great Rotation Source link
The Rest of the Story – Fat Tail Daily
Gold is telling its story. Reuters: ‘Gold prices gained around 1% on Thursday, fueled by strong expectations of a Federal Reserve rate cut in September with investors focusing on U.S. inflation data for further insights on the potential size of the cut. Spot gold rose 0.9% to $2,524.45 per ounce.’ On the surface, it is…
$1,918 Trading Auto Direction With ‘Supply Demand EA ProBot’
Hello traders, Today i used ‘Supply Demand EA ProBot’ with the ‘Automated Direction ‘ enabled. From the input parameters i enabled 2nd and 3rd timeframes above. “Nested Zones” filter was disabled. I wanted the EA to placed trades only on supply and demand zones that were in compliance with higher timeframes price action bias. The…
Lawsuit filed over measure approved by Arkansas voters that revoked planned casino’s license
LITTLE ROCK, Ark. (AP) — Cherokee Nation Entertainment on Friday filed a lawsuit challenging a constitutional amendment Arkansas voters approved this week that revokes its license for a planned casino in the state. The lawsuit filed in federal court claims the measure approved by voters on Tuesday violates its constitutional rights, and seeks to block…
Biocon shares in focus after successful results of Yesintek in Phase 3
Shares of Biocon will remain in focus on Monday, March 10, after the company announced that it has achieved positive results from a phase 3 study that compares Yesintek (Biocon Biologics’ biosimilar to Ustekinumab) with reference products. “Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523,…
